News

Prostamax is a product associated with bioregulator peptides that has been studied in experimental models of chronic aseptic inflammation of the prostate gland. Research has indicated that Prostamax can reduce the severity of symptoms associated with chronic inflammation, such as swelling, increased blood vessel redness, and lymphoid infiltration. Additionally, it has been found to prevent the development of sclerotic (hardening) and atrophic (tissue degeneration) processes in the prostate gland.

 

Studies have also shown that Prostamax has the ability to enhance sexual activity in animals. In comparison to other widely used prostatotropic agents derived from Serenoa repens extract and animal prostate tissue, Prostamax has demonstrated greater efficacy.